IP Library Granted Patent US 7,976,871
Granted Patent B2
US 7,976,871 · App. 11/134,631 · Granted Jul 12, 2011

Modified release composition of highly soluble drugs

Assignee: Torrent Pharmaceuticals Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,976,871
App. No.
11/134,631
Granted
Jul 12, 2011
Kind
B2
Abstract

A novel modified release dosage form comprising of a high solubility active ingredient, which utilizes dual retard technique to effectively reduce the quantity of release controlling agents. Present invention can optionally comprise additionally another active ingredient as an immediate release form or modified release form. Present invention also relates to a process for preparing the said formulation.

Claims (6)

1. A process for the preparation of a modified release dosage form comprising metformin hydrochloride prepared by using dual retard technique to control the release of metformin, wherein the said dual retard technique is a combination of a matrix formulation and a reservoir formulation, said process comprising:

a) preparing micro matrix particles consisting of metformin hydrochloride and one or more hydrophobic release controlling agents consisting of poly(ethyl acrylate, methyl methacrylate, trimethylammonioethyl methacrylate chloride) 1:2:O.1; poly(ethyl acrylate, methyl methacrylate, trimethylamonioethyl methacrylate chloride) 1:2:0.2; and poly(ethyl acrylate, methyl methacrylate) 2:1; and

b) coating said micro matrix articles with one or more hydrophobic release controlling agents selected from the group consisting of waxes selected from the group consisting of beeswax, carnauba wax, microcrystalline wax, and ozokerite; fatty alcohols selected from the group consisting of cetostearyl alcohol, stearyl alcohol; cetyl alcohol and myristyl alcohol; and fatty acid esters selected from the group consisting of glyceryl monostearate; glycerol monooleate, acetylated monoglycerides, tristearin, tripalmitin, cetyl esters wax, glyceryl palmitostearate, glyceryl behenate and hydrogenated castor oil.

2. A process according to claim 1 , wherein said micro matrix particles contain metformin hydrochloride and one or more hydrophobic release controlling agents are present in a weight ratio of from 100:2.5 to 100:30.

3. A process according to claim 1 wherein in said micro matrix particles, metformin hydrochloride can be less than or equal to 1500 mg.

4. A process according to claim 1 , wherein said micro matrix particles and coating of one or more of said hydrophobic release controlling agents are present in a weight ratio of from 100:1 to 100:30.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 7, 2011
From: VAYA, NAVIN; KARAN, RAJESH SINGH; NADKARNI, SUNIL SADANAND; GUPTA, VINOD KUMAR
To: TORRENT PHARMACEUTICALS LIMITED
Reel/Frame 026865/0047 →
Priority Claims (3)
IN 696/MUM/2003 · Aug 5, 2002 · national
IN 698/MUM/2002 · Aug 5, 2002 · national
IN 81/MUM/2003 · Jan 22, 2003 · national
Continuity (2)
Continuation In Part 10630348 · Jul 29, 2003
Related Publication 20060018933A1 · Jan 26, 2006